Table 2.

Unadjusted Changes in Outcome Measures from Baseline

Outcome Measure	Time	Spironolactone	Placebo	Difference Between Groups (95% CI)	P Value
6-min walking distance (m)	10 wk	27.4	27.5	−0.1 (−22.9 to 22.7)	.99
	20 wk	30.5	33.7	−3.2 (−28.9 to 22.5)	.81
Timed Up and Go test (s)	10 wk	−1.4	−1.2	−0.2 (−1.3 to 0.9)	.72
	20 wk	−1.3	−1.3	0.04 (−1.3 to 1.3)	.95
ISWT distance (m)	10 wk	13.9	17.6	−3.7 (−21.4 to 27.5)	.72
	20 wk	25.4	22.4	3.1 (−21.4 to 27.5)	.81
FLP total score	10 wk	−16	−17	1 (−45 to 47)	.97
	20 wk	−14	−22	8 (−49 to 64)	.78
EuroQol EQ-5D	10 wk	0.05	0.01	0.04 (−0.03 to 0.11)	.22
	20 wk	0.11	0.01	0.10 (0.03-0.18)	.006
EuroQol EQ-VAS	10 wk	4.2	2.8	1.5 (−4.3 to 7.2)	.62
	20 wk	−0.3	1.6	−1.9 (−8.3 to 4.5)	.55
HADS-D score	10 wk	−1.11	−0.25	−0.84 (−1.58 to −0.09)	.03
	20 wk	−0.23	−0.04	−0.20 (−0.97 to 0.58)	.62
HADS-A score	10 wk	−0.11	−0.23	0.12 (−0.83 to 1.09)	.80
	20 wk	0.33	−0.45	0.78 (−0.17 to 1.69)	.11

EQ-VAS = EuroQol Visual Analogue Scale; HADS = Hospital Anxiety and Depression Scale; ISWT = Incremental Shuttle Walk Test; FLP = Functional Limitation Profile.